D-AP4

Pricing Availability   Qty
Description: Broad spectrum glutamatergic antagonist
Chemical Name: D-(-)-2-Amino-4-phosphonobutyric acid
Purity: ≥98% (HPLC)
Datasheet
Citations (3)
Reviews
Literature (5)

Biological Activity for D-AP4

D-AP4 is a broad spectrum excitatory amino acid receptor antagonist. Also agonist at the quisqualate-sensitized AP6 site in hippocampus where it is less potent than L-AP4.

DL Mixture and L-isomer also available.

Technical Data for D-AP4

M. Wt 183.1
Formula C4H10NO5P
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 78739-01-2
PubChem ID 1550579
InChI Key DDOQBQRIEWHWBT-GSVOUGTGSA-N
Smiles N[C@@]([H])([C@](O)=O)CCP(O)(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for D-AP4

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
1eq. NaOH 100

Preparing Stock Solutions for D-AP4

The following data is based on the product molecular weight 183.1. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 5.46 mL 27.31 mL 54.61 mL
5 mM 1.09 mL 5.46 mL 10.92 mL
10 mM 0.55 mL 2.73 mL 5.46 mL
50 mM 0.11 mL 0.55 mL 1.09 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References for D-AP4

References are publications that support the biological activity of the product.

Davies and Watkins (1982) Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Res. 235 378 PMID: 6145492

Evans et al (1982) The effect of a series of ω-phosphonic-α-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65 PMID: 7042024

Schulte et al (1994) Utilization of the resolved L-isomer of 2-amino-6-phosphonhexanoic acid (L-AP6) as a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons. Brain Res. 649 203 PMID: 7953634


If you know of a relevant reference for D-AP4, please let us know.

View Related Products by Product Action

View all Non-selective Ionotropic Glutamate Antagonists

Keywords: D-AP4, D-AP4 supplier, Broad, spectrum, EAA, antagonists, Glutamate, Ionotropic, Non-Selective, iGluR, Receptors, mGlur, Metabotropic, Non-selective, mGlu, 0102, Tocris Bioscience

3 Citations for D-AP4

Citations are publications that use Tocris products. Selected citations for D-AP4 include:

Sexton and Gelder (2015) G-Protein Coupled Receptor Kinase 2 Minimally Regulates Melanopsin Activity in Intrinsically Photosensitive Retinal Ganglion Cells. PLoS One 10 e0128690 PMID: 26069965

France (2017) Multiple roles of GluN2B-containing NMDA receptors in synaptic plasticity in juvenile hippocampus. Neuropharmacology 112 76 PMID: 27523302

Sexton et al (2015) Type I intrinsically photosensitive retinal ganglion cells of early post-natal development correspond to the M4 subtype. Neural Dev 10 17 PMID: 26091805


Do you know of a great paper that uses D-AP4 from Tocris? Please let us know.

Reviews for D-AP4

There are currently no reviews for this product. Be the first to review D-AP4 and earn rewards!

Have you used D-AP4?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Ion Channel Product Listing

Ion Channel Product Listing

A collection of around 500 products for ion channel research, the listing includes research tools for the study of:

  • Ligand-gated ion channels
  • Voltage-gated ion channels
  • Other Ion Channels
Pain Research Product Guide

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Pain Poster

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.